# ✓ MetroPlusHealth MEMO

DATE - 07.13.23

TO: BEHAVIORAL HEALTH PROVIDERS

## RE: PROHIBITING COPAYS FOR TREATMENT AT AN OPIOID TREATMENT PROGRAM (OTP) | NYS SENATE BILL S5690

QUALIFIED HEALTH PLANS, ESSENTIAL PLANS, METROPLUS GOLD, GOLDCARE I & GOLDCARE II

#### **SUMMARY**

Consistent with the amendments to the State Health Insurance Law, **effective January 1, 2023**, health insurance plans are prohibited from imposing a copayment or coinsurance upon QHP, Essential Plan, Gold, and GoldCare I & Goldcare II members during the course of treatment in an opioid treatment program.

"Opioid Treatment Program" or OTP for purposes of the new rule means a program or practitioner engaged in opioid treatment of individuals with an opioid agonist treatment medication. This rule will prohibit multiple co-payments for OTP services for the duration of the treatment received.

### The prohibition:

- On copayments and coinsurance for treatment at an opioid treatment program applies to innetwork services only.
- On copayments and coinsurance to medication provided at an opioid treatment program for home use.
- Is not limited to opioid antagonist medications or the administration of such medication at an opioid treatment program. To the extent that other services are provided at an opioid treatment program, a policy is prohibited from imposing a copayment or coinsurance on such services is not limited to methadone treatment programs. Opioid treatment programs (OTPs) are OASAS-certified sites where medication to treat opioid dependency is administered. These medications can include methadone, buprenorphine, and suboxone. In addition to medications, OTPs also offer counseling services.

#### The prohibition does not apply to:

- If a policy contains a deductible. treatment at an opioid treatment program may be subject to the deductible.
- Copayments and coinsurance to medication obtained at a retail pharmacy.
- To the extent that Suboxone or other substance use disorder (SUD) medication is prescribed and obtained at a pharmacy, rather than administered at an opioid treatment program, a policy would not be prohibited from imposing the applicable prescription drug copayment or coinsurance.